Chiglitazar Explained

Tradename:	Bilessglu
Legal Status:	Rx in China
Synonyms:	Carfloglitazar
Cas Number:	743438-45-1
Pubchem:	71402018
Chemspiderid:	57523239
Unii:	E6EJV1J6Y0
Chembl:	4650349
Stdinchi:	1S/C36H29FN2O4/c37-26-17-15-25(16-18-26)35(40)30-9-1-4-10-31(30)38-32(36(41)42)23-24-13-19-27(20-14-24)43-22-21-39-33-11-5-2-7-28(33)29-8-3-6-12-34(29)39/h1-20,32,38H,21-23H2,(H,41,42)/t32-/m0/s1
Stdinchikey:	QNLWMPLUWMWDMQ-YTTGMZPUSA-N
Smiles:	C1=CC=C2C(=C1)C3=CC=CC=C3N2CCOC4=CC=C(C=C4)C[C@@H](C(=O)O)NC5=CC=CC=C5C(=O)C6=CC=C(C=C6)F
Iupac Name:	(2S)-3-[4-(2-carbazol-9-ylethoxy)phenyl]-2-[2-(4-fluorobenzoyl)anilino]propanoic acid
C:	36
H:	29
N:	2
O:	4
F:	1

Chiglitazar (trade name Bilessglu) is a drug for the treatment of type 2 diabetes.^[1] It is a peroxisome proliferator-activated receptor (PPAR) agonist.

In China, chiglitazar is approved for glycemic control in adult patients with type 2 diabetes when used in combination with diet and exercise.^[2]

Notes and References

Ji L, Song W, Fang H, Li W, Geng J, Wang Y, Guo L, Cai H, Yang T, Li H, Yang G, Li Q, Liu K, Li S, Liu Y, Shi F, Li X, Gao X, Tian H, Ji Q, Su Q, Zhou Z, Wang W, Zhou Z, Li X, Xu Y, Ning Z, Cao H, Pan D, Yao H, Lu X, Jia W . 6 . Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP) . Science Bulletin . 66 . 15 . 1571–1580 . August 2021 . 36654286 . 10.1016/j.scib.2021.03.019 . 233650336 . free . 2021SciBu..66.1571J .
Deeks ED . Chiglitazar: First Approval . Drugs . 82 . 1 . 87–92 . January 2022 . 34846697 . 10.1007/s40265-021-01648-1 . 244716275 .